Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL
NCT ID: NCT05414669
Last Updated: 2022-06-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
35 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-08-06
Study Completion Date
2021-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Extracorporeal shock wave lithotripsy (ESWL) is accepted as the first treatment choice for most urinary stones. Still, it has adverse effects on the kidneys. The mechanism underlying the shock wave induced renal injury is not entirely understood, and oxidative stress has been speculated to be involved in this process. The Investigator evaluated the role of allopurinol, which works as a xanthine oxidase inhibitor and free radical scavenger in renal protection against oxidative effects of ESWL. In a randomized, double-blind placebo-controlled trial, a total of 70 patients with renal stones undergoing ESWL were randomly assigned to 2 groups. Group 1 receive allopurinol, and group 2 receive a placebo. Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL. The urinary excretion of malondialdehyde (MDA), nitric oxide (NO), and kidney injury molecule-1 (KIM-1) were determined by quantitative double antibody sandwich direct ELISA at baseline before ESWL then repeatedly two h, and 24 h after ESWL. The resistive index (RI) change of the interlobar artery was asses along with the measurement of the shear wave velocity (SWV) in the focal zone of the treated kidney before, two weeks, and four weeks after ESWL. Multivariate analyses were performed using repeated measure ANOVA to control covariates.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation
NCT02373384
Urolithiasis
Renal Stones
COMPLETED
PHASE4
Use of Alfuzosin in Stone Treatment With ESWL
NCT00388271
Urinary Calculi
WITHDRAWN
PHASE3
Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus
NCT01215708
Renal Calculi
UNKNOWN
PHASE3
Medical Expulsive Therapy Post-SWL For Renal Stones
NCT05032287
Urologic Diseases
Urolithiasis
Stone, Kidney
COMPLETED
NA
Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones
NCT04819828
Renal Stone
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects with kidney stones who met the criteria were given a detailed explanation about this study by the research team, then followed by signing the informed consent. History was taken along with physical examination, complete blood count, Bun, creatinine, uric acid, urinalysis and also anthropometric measurements (weight and height). Then each subjects got one of the intervention drugs, either allopurinol 300mg or placebo. Allopurinol 300 mg was finely grounded and put into gelatin capsules. The placebo was made by using Saccharum lactis material which was inserted into a gelatin capsule as well. The shape, color, texture, and weight of the placebo capsules were made the same as the drug allopurinol. Allopurinol capsules and placebo were made by the Pharmacy section of Sanglah Hospital.
Subjects were randomly allocated using a permuted block method into the allopurinol or placebo group. Each subject received one type of capsule consisting of 3 capsules containing 300 mg allopurinol or placebo taken the day before ESWL, 2 hours before ESWL, and the day after ESWL.
The study was conducted double-blind where the researcher, subject, data collector, outcome adjudicator, and data analyst did not know the type of treatment. Medicines are given in sealed envelopes using an undisclosed code that will be uncovered at the end of the study.
For the preparation of ESWL subjects; each subjects got infusion of 0.9% NaCl with 20 drops per minute, ondansetron 8 mg i.v., pethidine bolus 50 mg i.v., followed by drip pethidine 50 mg and ketorolac 30 mg given in 500 ml NaCl 0.9% with 20 drops of 20 drops per minute.
The Investigator performed ESWL using a Siemen litostar vario which uses an electromagnetic generator. The number of shock waves given is 2500-3000 shock waves per session. The given shock wave strength is slim to 2 J in the initial 200 shock wave followed by 3 to 3.5 J in the remainder of the shock wave. The given shock wave frequency is 60 x/minute.
Urine samples were taken aseptically using the mid-portion method in the amount of 10 ml for examination of biomarkers KIM-1, NO, and MDA one hour before ESWL. Furthermore, the urine sample was taken 10 ml two hours after ESWL and one day after ESWL. Examination time after ESWL is calculated from the end of the ESWL session.
RI examination and renal SWV elastography were performed one hour before ESWL, followed by two weeks and one month after ESWL by the same radiology specialist.
Subject compliance with medication is evaluated based on the number of capsules taken from the entire drug administered. If the number of capsules taken is less, the subject will be excluded from the analysis. Adverse events or drug side effects are defined as unexpected events during the study, such as experiencing procedure-related complications or being allergic to allopurinol. The Investigator evaluated the subjects every week after ESWL to assess tolerance and possible side effects.
If there was any drug side effects or serious adverse events(SAE), the subjects were reported to the ethics committee as soon as possible, less than 24 hours from the first time they were discovered, and actions were carried out as quickly as possible until the series of events ends. SAE was written in detail on the SAE form, including the following; when it was first discovered, the manifestation of the incident, the conditions before the incident, the handling of the event, and the outcome.
If the subject experiences side effects such as allergic reactions (redness of the skin, swelling of the eyes or mouth) and severe gastrointestinal disturbances (vomiting, diarrhea), the subject will be excluded from the analysis. The subject will also be excluded from the analysis if they experience complications related to ESWL procedure such as ureteral obstruction, pain (VAS \> 5), or there were signs of infection. Subjects will be evaluated when visiting the hospital according to schedule, telephone contact, or by making a home visit.
The envelope of intervention data will be opened after data analysis, witnessed by an independent team, namely the Sanglah Hospital pharmacy and the Sanglah Hospital research division.
Subjects were randomly allocated using a permuted block method into the allopurinol or placebo group. Each subject received one type of capsule consisting of 3 capsules containing 300 mg allopurinol or placebo taken the day before ESWL, 2 hours before ESWL, and the day after ESWL.
The study was conducted double-blind where the researcher, subject, data collector, outcome adjudicator, and data analyst did not know the type of treatment. Medicines are given in sealed envelopes using an undisclosed code that will be uncovered at the end of the study.
For the preparation of ESWL subjects; each subjects got infusion of 0.9% NaCl with 20 drops per minute, ondansetron 8 mg i.v., pethidine bolus 50 mg i.v., followed by drip pethidine 50 mg and ketorolac 30 mg given in 500 ml NaCl 0.9% with 20 drops of 20 drops per minute.
The Investigator performed ESWL using a Siemen litostar vario which uses an electromagnetic generator. The number of shock waves given is 2500-3000 shock waves per session. The given shock wave strength is slim to 2 J in the initial 200 shock wave followed by 3 to 3.5 J in the remainder of the shock wave. The given shock wave frequency is 60 x/minute.
Urine samples were taken aseptically using the mid-portion method in the amount of 10 ml for examination of biomarkers KIM-1, NO, and MDA one hour before ESWL. Furthermore, the urine sample was taken 10 ml two hours after ESWL and one day after ESWL. Examination time after ESWL is calculated from the end of the ESWL session.
RI examination and renal SWV elastography were performed one hour before ESWL, followed by two weeks and one month after ESWL by the same radiology specialist.
Subject compliance with medication is evaluated based on the number of capsules taken from the entire drug administered. If the number of capsules taken is less, the subject will be excluded from the analysis. Adverse events or drug side effects are defined as unexpected events during the study, such as experiencing procedure-related complications or being allergic to allopurinol. The Investigator evaluated the subjects every week after ESWL to assess tolerance and possible side effects.
If there was any drug side effects or serious adverse events(SAE), the subjects were reported to the ethics committee as soon as possible, less than 24 hours from the first time they were discovered, and actions were carried out as quickly as possible until the series of events ends. SAE was written in detail on the SAE form, including the following; when it was first discovered, the manifestation of the incident, the conditions before the incident, the handling of the event, and the outcome.
If the subject experiences side effects such as allergic reactions (redness of the skin, swelling of the eyes or mouth) and severe gastrointestinal disturbances (vomiting, diarrhea), the subject will be excluded from the analysis. The subject will also be excluded from the analysis if they experience complications related to ESWL procedure such as ureteral obstruction, pain (VAS \> 5), or there were signs of infection. Subjects will be evaluated when visiting the hospital according to schedule, telephone contact, or by making a home visit.
The envelope of intervention data will be opened after data analysis, witnessed by an independent team, namely the Sanglah Hospital pharmacy and the Sanglah Hospital research division.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Kidney Calculi
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
The Key envelope was kept by third party and will be opened once the data analysis is done.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional group
Allopurinol 300 mg was administered orally for a total of 3 days, starting from the day before ESWL
Group Type
EXPERIMENTAL
Allopurinol Tablet 300 mg
Intervention Type
DRUG
Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
Control Group
Placebo was administered orally for a total of 3 days, starting from the day before ESWL
Group Type
PLACEBO_COMPARATOR
Control Group
Intervention Type
DRUG
Placebo was given orally for a total of 3 days, beginning a day before ESWL.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol Tablet 300 mg
Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
Intervention Type
DRUG
Control Group
Placebo was given orally for a total of 3 days, beginning a day before ESWL.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Allopurinol
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with renal stone who meet ESWL criteria
* Age 18 to 59 years old
* Consent to join this study
* Age 18 to 59 years old
* Consent to join this study
Exclusion Criteria
* Patient with Diabetes Melitus
* Patient with hypertension
* Patient with Chronic Kidney Disease stage IV and stage V
* Patient with urinary tract infection
* Patient with obesity
* Patient with uric acid more than 9mg/dL
* Patient with hypertension
* Patient with Chronic Kidney Disease stage IV and stage V
* Patient with urinary tract infection
* Patient with obesity
* Patient with uric acid more than 9mg/dL
Minimum Eligible Age
18 Years
Maximum Eligible Age
59 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanglah General Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kadek Budi Santosa
Urologist
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kadek B Santosa, Urologist
Role: PRINCIPAL_INVESTIGATOR
Sanglah General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanglah General Hospital
Denpasar, Bali, Indonesia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Indonesia
References
Explore related publications, articles, or registry entries linked to this study.
Acharya, C.R., Sharma, A.K., and Kantharia, N.D. 2015. Involvement of oxidative stress in patients of gout and antioxidant effect of allopurinol. International Journal of Medical Science and Public Health; 4(2): pp 168 -172
Reference Type
BACKGROUND
Aksoy H, Aksoy Y, Turhan H, Keles S, Ziypak T, Ozbey I. The effect of shock wave lithotripsy on nitric oxide and malondialdehyde levels in plasma and urine samples. Cell Biochem Funct. 2007 Sep-Oct;25(5):533-6. doi: 10.1002/cbf.1349.
Reference Type
BACKGROUND
Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP, Poggio E, Glassock RJ, Rule AD. Single-Nephron Glomerular Filtration Rate in Healthy Adults. N Engl J Med. 2017 Jun 15;376(24):2349-2357. doi: 10.1056/NEJMoa1614329.
Reference Type
BACKGROUND
Alirezaei, A., Argani, H., Asgharpour, M., Bahadorimonfared, A., and Bakhtiyari, M. 2017. An update on allopurinol and kidney failure; new trend for an old drug. J Renal Inj Prev; 6(4): pp 297-302
Reference Type
BACKGROUND
Alessio HM. 2000. In: Handbook of oxidants and antioxidants in exercise. Hanninen O, Packy L, Sen CK, editors. Elsevier; Amsterdam; pp 115-128
Reference Type
BACKGROUND
Asnita Arif, Nurlaily Idris, Bachtiar Murtala, Andi Alfian Z, Sri Asriyani, and Hasyim Kasim. 2019. The Correlation Between Renal Shear Wave Elastography with Estimated Glomerular FiltrationRate in Chronic Kidney Disease. Jurnal Kedokteran Brawijaya; 30(4): pp 287-292
Reference Type
BACKGROUND
Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004 Mar 16;555(Pt 3):589-606. doi: 10.1113/jphysiol.2003.055913. Epub 2003 Dec 23.
Reference Type
BACKGROUND
Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 2009 Nov;24(11):3265-8. doi: 10.1093/ndt/gfp010. Epub 2009 Mar 23. No abstract available.
Reference Type
BACKGROUND
Bonventre JV. Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl (2011). 2014 Nov;4(1):39-44. doi: 10.1038/kisup.2014.8.
Reference Type
BACKGROUND
Brian R, Matlaga, Amy E. Krambeck, and James E. Lingeman. 2016. Surgical management of Upper Urinary Tract Calculi. Campbell-Walsh urology. Philadelphia: Elsevier; pp 1260-1276
Reference Type
BACKGROUND
Burne-Taney MJ, Ascon DB, Daniels F, Racusen L, Baldwin W, Rabb H. B cell deficiency confers protection from renal ischemia reperfusion injury. J Immunol. 2003 Sep 15;171(6):3210-5. doi: 10.4049/jimmunol.171.6.3210.
Reference Type
BACKGROUND
Busti A.J. 2015. The Differences in the Mechanisms of Action Between Allopurineol and Febuxostat. Available at: http://www.ebmconsult.com/articles/allopurinol\ and febuxostat-zyloprim-uloric-uric-acid-gout-mechanism. Accesed 9th August 2016
Reference Type
BACKGROUND
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014 Jul 3;371(1):58-66. doi: 10.1056/NEJMra1214243. No abstract available.
Reference Type
BACKGROUND
Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Jun;53(6):961-73. doi: 10.1053/j.ajkd.2008.11.034. Epub 2009 Apr 5.
Reference Type
BACKGROUND
Dahlan, M. Sopiyudin. 2009. Besar Sampel dan Pengambilan Sampel, dalam Penelitian Kedokteran dan Kesehatan. Jakarta: Salemba Medika
Reference Type
BACKGROUND
Clark DL, Connors BA, Evan AP, Willis LR, Handa RK, Gao S. Localization of renal oxidative stress and inflammatory response after lithotripsy. BJU Int. 2009 Jun;103(11):1562-8. doi: 10.1111/j.1464-410X.2008.08260.x. Epub 2009 Jan 20.
Reference Type
BACKGROUND
Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623-44. doi: 10.2165/00003088-200746080-00001.
Reference Type
BACKGROUND
de Geus HR, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J. 2012 Apr;5(2):102-108. doi: 10.1093/ckj/sfs008.
Reference Type
BACKGROUND
Denise grotto, lucas santa maria, Juliana Valentini, clóvis paniz, and gabriela schmitt e solange cristina garcia. 2009. Importance of the Lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. Quim. Nova; 32(1): pp 169-174
Reference Type
BACKGROUND
De Rosa S, Antonelli M, Ronco C. Hypothermia and kidney: a focus on ischaemia-reperfusion injury. Nephrol Dial Transplant. 2017 Feb 1;32(2):241-247. doi: 10.1093/ndt/gfw038.
Reference Type
BACKGROUND
Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006 Jun;17(6):1503-20. doi: 10.1681/ASN.2006010017. Epub 2006 May 17. No abstract available.
Reference Type
BACKGROUND
Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960. doi: 10.1155/2014/406960. Epub 2014 Jul 20.
Reference Type
BACKGROUND
Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000 Dec;15(3-4):290-301. doi: 10.1007/s004670000461.
Reference Type
BACKGROUND
Erol T, Tekin A, Katircibasi MT, Sezgin N, Bilgi M, Tekin G, Zumrutdal A, Sezgin AT, Muderrisoglu H. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013 Aug 20;167(4):1396-9. doi: 10.1016/j.ijcard.2012.04.068. Epub 2012 May 8.
Reference Type
BACKGROUND
Fahmy N, Sener A, Sabbisetti V, Nott L, Lang RM, Welk BK, Mendez-Probst CE, MacPhee RA, VanEerdewijk S, Cadieux PA, Bonventre JV, Razvi H. Urinary expression of novel tissue markers of kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J Endourol. 2013 Dec;27(12):1455-62. doi: 10.1089/end.2013.0188. Epub 2013 Nov 1.
Reference Type
BACKGROUND
Fegan JE, Husmann DA, Alexander ME, Feagins B, and Preminger GM. 2009. Preservation of renal architecture durineg extracorporeal shock wave lithotripsy. J Endourol/Endourol Soc; 5: pp 273-6
Reference Type
BACKGROUND
Garg AX, Parikh CR. Yin and Yang: acute kidney injury and chronic kidney disease. J Am Soc Nephrol. 2009 Jan;20(1):8-10. doi: 10.1681/ASN.2008111197. Epub 2008 Dec 31. No abstract available.
Reference Type
BACKGROUND
George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-72. doi: 10.2147/vhrm.s4265. Epub 2009 Apr 8.
Reference Type
BACKGROUND
Graham S, Day RO, Wong H, McLachlan AJ, Bergendal L, Miners JO, Birkett DJ. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol. 1996 Apr;41(4):299-304. doi: 10.1046/j.1365-2125.1996.03116.x.
Reference Type
BACKGROUND
Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003 Dec;112(11):1644-54. doi: 10.1172/JCI18817.
Reference Type
BACKGROUND
Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002 Jul;62(1):237-44. doi: 10.1046/j.1523-1755.2002.00433.x.
Reference Type
BACKGROUND
Hatipoglu NK, Evliyaoglu O, Isik B, Bodakci MN, Bozkurt Y, Sancaktutar AA, Soylemez H, Atar M, Penbegul N, Yunce M, Daggulli M. Antioxidant signal and kidney injury molecule-1 levels in shockwave lithotripsy induced kidney injury. J Endourol. 2014 Feb;28(2):224-8. doi: 10.1089/end.2013.0535. Epub 2013 Nov 9.
Reference Type
BACKGROUND
Hirschberg R. Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J Am Soc Nephrol. 2005 Jan;16(1):9-11. doi: 10.1681/ASN.2004110901. Epub 2004 Dec 1. No abstract available.
Reference Type
BACKGROUND
Hobarth K, Maier A, Hofbauer J, Marberger M. Color flow Doppler sonography for extracorporeal shock wave lithotripsy. J Urol. 1993 Dec;150(6):1768-70. doi: 10.1016/s0022-5347(17)35890-1.
Reference Type
BACKGROUND
Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003 Dec;112(12):1776-84. doi: 10.1172/JCI20530.
Reference Type
BACKGROUND
Kira VM, Fagundes DJ, Bandeira CO, Kaufman O, Fagundes AT, Ortiz V. Effects of repeated extracorporeal shock wave on kidney apoptosis of normal and diabetic rat. Int Braz J Urol. 2008 Jan-Feb;34(1):91-6. doi: 10.1590/s1677-55382008000100013.
Reference Type
BACKGROUND
Kostic D.a., Dimitrijevic D.S., Stojanovic G.S., Palic I.R., Dordevic A.S., and Ickovski J.D. 2015. Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition. Journal of Chemistry; available at https://doi.org/10.1155/2015/294858
Reference Type
BACKGROUND
Kou B, Ni J, Vatish M, Singer DR. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis. Microcirculation. 2008 Apr;15(3):251-67. doi: 10.1080/10739680701651495.
Reference Type
BACKGROUND
Kurt S, Tokgoz O, Tokgoz H, Voyvoda N. Evaluation of effects of Extracorporeal Shock Wave Lithotripsy on renal vasculature with Doppler ultrasonography. Med Ultrason. 2013 Dec;15(4):273-7. doi: 10.11152/mu.2013.2066.154.sk2.
Reference Type
BACKGROUND
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 Jun;67(6):2089-100. doi: 10.1111/j.1523-1755.2005.00365.x.
Reference Type
BACKGROUND
Li B, Zhou W, Li P. Protective effects of nifedipine and allopurinol on high energy shock wave induced acute changes of renal function. J Urol. 1995 Mar;153(3 Pt 1):596-8.
Reference Type
BACKGROUND
Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004 Jan;15(1):1-12. doi: 10.1097/01.asn.0000106015.29070.e7.
Reference Type
BACKGROUND
Macias-Nunez JF, Revert M, Fiksen-Olsen M, Knox FG, Romero JC. Effect of allopurinol on the renovascular responses to adenosine. J Lab Clin Med. 1986 Jul;108(1):30-6.
Reference Type
BACKGROUND
Margaret S. Pearle, and Yair Lotan. 2016. Urineary Lithiasis; Etiology, Epidemiology, and Pathogenesis. Campbell-Walsh urology. Philadelphia: Elsevier, pp.1363-1391
Reference Type
BACKGROUND
McClintock DS, Santore MT, Lee VY, Brunelle J, Budinger GR, Zong WX, Thompson CB, Hay N, Chandel NS. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. Mol Cell Biol. 2002 Jan;22(1):94-104. doi: 10.1128/MCB.22.1.94-104.2002.
Reference Type
BACKGROUND
McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE. PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics. 2014 Sep;24(9):464-76. doi: 10.1097/FPC.0000000000000058. No abstract available.
Reference Type
BACKGROUND
Miller NL, Evan AP, Lingeman JE. Pathogenesis of renal calculi. Urol Clin North Am. 2007 Aug;34(3):295-313. doi: 10.1016/j.ucl.2007.05.007.
Reference Type
BACKGROUND
Munver R, Delvecchio FC, Kuo RL, Brown SA, Zhong P, Preminger GM. In vivo assessment of free radical activity during shock wave lithotripsy using a microdialysis system: the renoprotective action of allopurinol. J Urol. 2002 Jan;167(1):327-34.
Reference Type
BACKGROUND
Nakao T, Ushigome H, Nakamura T, Harada S, Koshino K, Suzuki T, Ito T, Nobori S, Yoshimura N. Evaluation of renal allograft fibrosis by transient elastography (Fibro Scan). Transplant Proc. 2015 Apr;47(3):640-3. doi: 10.1016/j.transproceed.2014.12.034.
Reference Type
BACKGROUND
Mercimek MN, Ender O. Effect of urinary stone disease and its treatment on renal function. World J Nephrol. 2015 May 6;4(2):271-6. doi: 10.5527/wjn.v4.i2.271.
Reference Type
BACKGROUND
Weimert NA, Tanke WF, Sims JJ. Allopurinol as a cardioprotectant during coronary artery bypass graft surgery. Ann Pharmacother. 2003 Nov;37(11):1708-11. doi: 10.1345/aph.1D023.
Reference Type
BACKGROUND
Kwon O, Hong SM, Ramesh G. Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol. 2009 Jan;296(1):F25-33. doi: 10.1152/ajprenal.90531.2008. Epub 2008 Oct 29.
Reference Type
BACKGROUND
Ozkan F, Goya C, Yildiz S, Duymus M, Menzilcioglu SM, and Avcu S. 2016. Ultrasound elastography in kidney disease. In: Patel VB, Preedy VR (ed), Biomarkers in Kidney Disease, Biomarkers in Disease: Methods, Discoveries and Applications; pp 1052-1072
Reference Type
BACKGROUND
Ozturk A, Grajo JR, Dhyani M, Anthony BW, Samir AE. Principles of ultrasound elastography. Abdom Radiol (NY). 2018 Apr;43(4):773-785. doi: 10.1007/s00261-018-1475-6.
Reference Type
BACKGROUND
Platt JF. Duplex Doppler evaluation of native kidney dysfunction: obstructive and nonobstructive disease. AJR Am J Roentgenol. 1992 May;158(5):1035-42. doi: 10.2214/ajr.158.5.1566663.
Reference Type
BACKGROUND
Pocock J. Stuart. 2013. Clinical Trials a Practical Approach. New York: Jon Wiley and Son-Brisbane-Toronto
Reference Type
BACKGROUND
Pozniak, M., and Allan, P. 2014. Clinical doppler ultrasound (3rd ed). Philadelphia: Chucill-Livingstone Elsevier; pp 193-213
Reference Type
BACKGROUND
Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol. 2006;(176 Pt 1):1-40. doi: 10.1007/3-540-32967-6_1.
Reference Type
BACKGROUND
Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012 May;59(3):235-42. doi: 10.1016/j.jjcc.2012.01.013. Epub 2012 Mar 6.
Reference Type
BACKGROUND
Rosenblum ER, Gavaler JS, Van Thiel DH. Lipid peroxidation: a mechanism for alcohol-induced testicular injury. Free Radic Biol Med. 1989;7(5):569-77. doi: 10.1016/0891-5849(89)90034-8.
Reference Type
BACKGROUND
Sagor MA, Tabassum N, Potol MA, Alam MA. Xanthine Oxidase Inhibitor, Allopurinol, Prevented Oxidative Stress, Fibrosis, and Myocardial Damage in Isoproterenol Induced Aged Rats. Oxid Med Cell Longev. 2015;2015:478039. doi: 10.1155/2015/478039. Epub 2015 Jun 7.
Reference Type
BACKGROUND
Santoso dan Singgih. 2016. Statistik Parametrik Konsep dan Aplikasi dengan SPSS. Edisi Revisi.Jakarta: Media Komputindo (Gramedia).
Reference Type
BACKGROUND
Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, Ni Z, Mou S. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014 Jan 3;9(1):e84131. doi: 10.1371/journal.pone.0084131. eCollection 2014.
Reference Type
BACKGROUND
Shaw CA, Taylor EL, Megson IL, Rossi AG. Nitric oxide and the resolution of inflammation: implications for atherosclerosis. Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:67-71. doi: 10.1590/s0074-02762005000900012. Epub 2005 Jun 14.
Reference Type
BACKGROUND
Singh H, Panta OB, Khanal U, Ghimire RK. Renal Cortical Elastography: Normal Values and Variations. J Med Ultrasound. 2017 Oct-Dec;25(4):215-220. doi: 10.1016/j.jmu.2017.04.003. Epub 2017 May 31.
Reference Type
BACKGROUND
Singh, I. and Strandhoy, J W. 2012. Pathophysiology of Urineary Tract Obstruction. In: Wein, A.J. Kavoussi, L.R. Novick, A.C. Partin, A.W.Peters, C.A. Editors. Campbell-Walsh Urology, 10th Ed. Saunders. Esevier. Philadelphia
Reference Type
BACKGROUND
Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016 Apr;12(4):235-42. doi: 10.1038/nrrheum.2015.132. Epub 2015 Sep 29.
Reference Type
BACKGROUND
Thurston MM, Phillips BB, Bourg CA. Safety and efficacy of allopurinol in chronic kidney disease. Ann Pharmacother. 2013 Nov;47(11):1507-16. doi: 10.1177/1060028013504740. Epub 2013 Oct 9.
Reference Type
BACKGROUND
Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006 Feb;67(2):227-35. doi: 10.1002/ccd.20598.
Reference Type
BACKGROUND
Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal Doppler sonography: where do we stand? AJR Am J Roentgenol. 2003 Apr;180(4):885-92. doi: 10.2214/ajr.180.4.1800885. No abstract available.
Reference Type
BACKGROUND
Vadas M. and Limaye v. 2005. The vascular endothelium: structure and function. In: Fitridge R. and Thompson M., editors. Mechanisms of Vascular Disease: A Textbook for Vascular Surgeons. Cambridge University Press: pp 1-10
Reference Type
BACKGROUND
Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H. Kidney injury molecule-1 in renal disease. J Pathol. 2010 Jan;220(1):7-16. doi: 10.1002/path.2642.
Reference Type
BACKGROUND
Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006 Apr;17(4):1143-50. doi: 10.1681/ASN.2005091017. Epub 2006 Feb 22.
Reference Type
BACKGROUND
Yalavarthy R, Edelstein CL. Therapeutic and predictive targets of AKI. Clin Nephrol. 2008 Dec;70(6):453-63. doi: 10.5414/cnp70453.
Reference Type
BACKGROUND
Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010 May;16(5):535-43, 1p following 143. doi: 10.1038/nm.2144. Epub 2010 May 2.
Reference Type
BACKGROUND
Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006 Jan;69(2):213-7. doi: 10.1038/sj.ki.5000054.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020.03.1.0645
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone ≤ 1cm
NCT05150899
UNKNOWN
Adjunct Inversion for Lower Pole Stone
NCT01852669
COMPLETED
NA
Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention
NCT06819111
NOT_YET_RECRUITING
PHASE1
Endourological Management of Stones During COVID19
NCT05293262
COMPLETED
Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A Randomized Controlled Trial
NCT04557202
COMPLETED
PHASE3
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
NCT01560091
WITHDRAWN
PHASE3
Tamsulosin Assisted Ureteral Access Sheath Insertion
NCT05197088
UNKNOWN
PHASE3
Acoustic Enhancer Research on Laser Lithotripsy (AEROLITH)
NCT04563039
COMPLETED
NA
Litholytic Therapy for Coral Urate Nephrolithiasis
NCT07162974
COMPLETED
NA
Study of the Administration of a Food Supplement in Patients With Lithiasis Treated With Extracorporeal Shock Wave Lithotripsy.
NCT05525130
COMPLETED
NA
Urinary NGAL and KIM-1 After ESWL
NCT07341269
COMPLETED
Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease
NCT06158620
RECRUITING
PHASE1/PHASE2
CaOx Stone Prevention
NCT07225764
RECRUITING
PHASE4
Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones
NCT01533389
COMPLETED
PHASE4
Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis
NCT01329042
COMPLETED
PHASE4
Ureteric Stenting Versus Non-stenting Following Uncomplicated Ureteroscopic Lithotripsy
NCT04145063
COMPLETED
NA
A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones
NCT00583258
WITHDRAWN
NA
The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones
NCT00451061
UNKNOWN
PHASE4
Extra-Corporeal Shock Wave Lithotripsy for Renal and Upper Ureteral Stones in Adults Under Locally Infiltrate d Anaesthetics ; a Clinical Randomized Controlled Study
NCT06462573
NOT_YET_RECRUITING
EARLY_PHASE1
The Role of Ureteral Stenting Following Uncomplicated Ureteroscopy for Ureteral and Renal Stones: A Randomized, Controlled Trial
NCT03130907
COMPLETED
NA
Maintenance of an Antiaggregation by Acetylsalicylic Acid, While a Extracorporeal Lithotripsy Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study
NCT03437057
RECRUITING
NA
Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus
NCT01010048
UNKNOWN
PHASE4
Ureteral Stenting After Ureteroscopy for Stone Treatment, A Global Perspective on Indications and Outcomes
NCT03567421
COMPLETED
Study of the Crystallization Inhibition Capacity of the Uric Acid in Urine in a Group of Lithiasic Patients After Intake of a Food Supplement
NCT03483532
COMPLETED
THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS
NCT06124066
COMPLETED
PHASE4